Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Solid Tumor 1

Interventions

Radiotherapy 39pembrolizumab 37Carboplatin 37Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Magnetic Resonance Spectroscopy 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Cyclophosphamide 15osimertinib 14Radiation 13Irinotecan 13Etoposide 13Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 9Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × ensartinib × Clear all
NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
12 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03536481 2019-07-24

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
74 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡